Role of Oncostatin M in the prognosis of inflammatory bowel disease: A meta-analysis

BACKGROUND Oncostatin M(OSM)is a pleiotropic cytokine which is implicated in the path-ogenesis of inflammatory bowel disease(IBD).AIM To evaluate the prognostic role of OSM in IBD patients.METHODS Literature search was conducted in electronic databases(Google Scholar,Embase,PubMed,Science Direct,Springer,and Wiley).Studies were selected if they reported prognostic information about OSM in IBD patients.Outcome data were synthesized,and meta-analyses were performed to estimate standardized mean differences(SMDs)in OSM levels between treatment responders and non-res-ponders and to seek overall correlations of OSM with other inflammatory bio-markers.RESULTS Sixteen studies(818 Crohn’s disease and 686 ulcerative colitis patients treated with anti-tumor necrosis factor-based therapies)were included.OSM levels were associated with IBD severity.A meta-analysis found significantly higher OSM levels in non-responders than in responders to therapy[SMD 0.80(0.33,1.27);P=0.001],in non-remitters than in remitters[SMD 0.75(95%CI:0.35 to 1.16);P<0.0001]and in patients with no mucosal healing than in those with mucosal heal-ing[SMD 0.63(0.30,0.95);P<0.0001].Area under receiver operator curve values showed considerable variability between studies but in general higher OSM levels were associated with poor prognosis.OSM had significant correlations with Simple Endoscopic Score of Crohn’s disease[r=0.47(95%CI:0.25 to 0.64);P<0.0001],Mayo Endoscopic Score[r=0.35(95%CI:0.28 to 0.41);P<0.0001],fecal calprotectin[r=0.19(95%CI:0.08 to 0.3);P=0.001],C-reactive protein[r=0.25(95%CI:0.11 to 0.39);P<0.0001],and platelet count[r=0.28(95%CI:0.17 to 0.39);P<0.0001].CONCLUSION OSM is a potential candidate for determining the severity of disease and predicting the outcomes of anti-tumor necrosis factor-based therapies in IBD patients.

IMMUNOLOGICAL CHARACTERISTICS OF THE LEUKEMIA CELLS TRANSFECTED WITH ONCOSTATIN M GENE BY RECOMBINANT ADENOVIRUS

In the present study, FBL3 murine erythroleukemia cells were transfected with human OSM(hOSM) gene by recombinant adenovirus, then the immunological properties of hOSM genetransfected FBL3 cells(FBL3OSM+) were investigated. 4 hours after transfection with hOSM gene, hOSM could be detected in the supernatant of FBL3OSM+ cells and hOSM secretion peaked at 24 h. The proliferation of FBL3OSM+ cells was inhibited markedly. The clonal formation of FBL3OSM+ cells was suppressed more obviously in comparison with wildtype FBL3 cells when analysed in clonal argar culture. Flow cytometry analysis showed that FBL3OSM+ cells expressed higher levels of Fas protein, B7 and ICAM1 molecules.FBL3OSM+ cells also expressed higher level of MHC class I molecules(H2Kb) but remained unchanged in expression of MHC class II molecules (Ia). CD14, which is a specific marker of monocyte/macrophage and not expressed on the wildtype FBL3 cells, was also detected on the surface of FBL3OSM+ cells. The results suggested that OSM gene transfer could increase the immunogenicity of FBL3 cells and promote their differentiation into macrophagelike cells. The data outline a promising approach to OSM gene therapy of leukemia mediated by recombinant adenovirus.

Correlation of Levels of Oncostatin M Cytokine in Crevicular Fluid and Serum in Periodontal Disease

Aim The aim of this study was to measure the level of Oncostatin M （OSM） a gp130 cytokine in the gingival crevicular fluid （GCF） and serum of chronic periodontitis patients and to find any correlation between them before and after periodontal therapy （scaling and root planing,SRP）. Methodology 60 subjects （age 25-50 years） were enrolled into three groups （n=20 per group）,group Ⅰ （healthy）,group Ⅱ （gingivitis） and group III （chronic periodontitis）. Group Ⅲ subjects were followed for 6-8 weeks after the initial periodontal therapy （SRP） as the group Ⅳ （after periodontal therapy）. Clinical parameters were assessed as gingival index （GI）,probing depth （PD）,clinical attachment level （CAL）,and radiographic evidence of bone loss. GCF and serum levels of OSM were measured by using Enzyme Linked Immunosorbent Assay （ELISA）. Results It was found that mean OSM levels had been elevated in both the GCF and serum of chronic periodontitis subjects （726.65 ± 283.56 and 65.59 ± 12.37 pg·mL-1,res-pectively） and these levels were decreased proportionally after the periodontal therapy （95.50 ± 38.85 and 39.98 ± 16.69 pg·mL-1 respectively）. However,OSM was detected in GCF of healthy subjects （66.15 ± 28.10 pg·mL-1） and gingivitis-suffering subjects （128.33 ± 22.96 pg·mL-1） and was found as below the detectable limit （≈0.0 pg·mL-1） in the serum of same subjects. Significant correlation has been found between clinical parameters and GCF-serum levels of OSM. Conclusion Increased OSM level both in the GCF and serum,and the decreased levels after initial periodontal therapy （SRP） may suggest a use as an inflammatory bio-marker in the periodontal disease.

基线血Oncostatin M水平对肾动脉狭窄患者新发心血管事件的预测价值

目的:检测肾动脉狭窄(RAS)患者血Oncostatin M(OSM)基线水平并探讨其对心血管事件的预测价值。方法:790例拟诊冠心病患者行冠状动脉造影同时行肾动脉造影术,获取资料、检测血OSM水平并随访12个月,观察随访期间新发生的主要不良心脏事件(MACE)。结果:122例(15.4%)患者存在≥50%的RAS,其中狭窄≥75%为31例(3.9%),50%~74%为91例(11.5%)。RAS患者高血压、高血脂及冠脉3支病变比例升高,年龄、收缩压、舒张压、血清同型半胱氨酸(Hcy)以及OSM水平显著高于无RAS患者。多变量Logistic回归分析显示,除年龄、高血压及冠脉3支病变外,基线血清OSM水平为RAS的独立危险因素。基线血清OSM水平较高的患者因心脏事件再次入院的比例显著升高(25.7%vs 5.8%,P=0.008)。多因素分析显示,矫正混杂因素后,基线血清OSM水平与MACE相关(HR=1.189,95%CI为1.117~1.264,P<0.05)。结论:RAS患者血清OSM水平显著升高,为RAS的独立危险因素,基线血OSM水平与RAS患者新发心血管不良事件相关。

Efforts of Transgene Oncostatin M on the Development of Retinal Neuron in Transgenic Mice

Purpose:Oncostatin M(OSM) is a cytokine released by macrophages and lymphocytesthat can function as a growth regulator. A current study shows that leukemia inhibitoryfactor (LIF), a homologue of OSM, can prevent photoreceptor cell death when expressedin the lens of transgenic mice. We determined the efforts of lens-specific overexpressionof OSM on the development of eye.Methods: A truncated mouse OSM cDNA ( ～ 660 bp) was linked to the αA-crytallinpromoter, and injected into single-cell embryos with microinjection. Then, transgenic micewere established. The mRNA expression of transgene OSM was detected by in situhybridization. Immunohistochemistry was used to detect the expression of syntaxin, glialfibrillary acidic protein (GFAP), synaptophysin in the retinas of transgenic mice.Results: At embryonic day (E 17.5), the expression of the syntaxin at the inner and midportion of the retinas of transgenic mice was much higher than that of the retinas ofnon-transgenic mice. The expression of GFAP was detected in the retinas of transgenicmice, while no expression in non-transgenic normal FVB(FVB/N) mice was detected inthis stage. At postnatal day one (P1), the expression of synaptophysin was detected inthe retinas of transgenic mice, but there was no such expression in FVB/N mice.Conclusions: Lens-specific overexpression of OSM induces premature differentiation ofamacrine cells, gial cells, and photoreceptors in vivo.

woLiver Regeneration Effect of Oncostatin M Following Hepatectomy for the Rat Cirrhotic Liver Model

Background/Aims: Liver resection represents the treatment of choice for hepatocellular carcinoma (HCC) arising in well-compensated cirrhosis. Gene expression of the multifunctional cytokine, Oncostatin M (OSM), stimulates liver regeneration and adenoviral vector expressing OSM (AdOSM) allows a persistent expression of the gene. The aim of this study is to evaluate the benefits of the preoperative injection of AdOSM to the remnant lobes to regenerate the liver. Methods: A 70% partial hepatectomy was performed in dimethylnitrosamine-administrated cirrhotic rats with a preoperative injection of AdOSM, adenoviral vector carrying β-galactosidase (AdLacZ), or phosphate-buffered saline (PBS). The morphologic, histologic, and biochemical changes in the remnant liver and survival rates were then assessed. Results: Portal injection with clamping the portal branches of the resected lobes for 5 min made it possible to effectively transduce the adenoviral vector into the remnant lobes. The ratio of the remnant liver weight/body weight (%) was 2.3 ± 0.5 in the AdOSM group, 1.1 ± 0.3 in the AdLacZ group (p < 0.001), and 1.6 ± 0.4 in the PBS group (p = 0.02). The fibrous ratio (%) was 21.3 ± 4.6 in the AdOSM group and 35.2 ± 4.5 in the AdLacZ group on day 4 after hepatectomy and fibrous status was significantly decreased in the AdOSM group (p = 0.02). Serum hyaluronic acid which is the indicator of liver fibrosis was 215 ± 141 ng/mL in the AdOSM group and 1963 ± 1225 ng/mL in the AdLacZ group (p = 0.03). Conclusions: The OSM gene therapy may increase the possibility of hepatectomy in a cirrhotic liver by improving fibrosis, hepatic function, and hepatocyte regeneration.

血清抑瘤素M联合组蛋白H4在脓毒症诊断及预后评估中的意义

目的探讨血清抑瘤素M(OSM)联合组蛋白H4在脓毒症诊断及预后评估中的意义。方法选择2020年9月至2021年8月合肥市第一人民医院41例脓毒症病人为研究对象,使用酶联免疫吸附(ELISA)法测定脓毒症病人血清中抑瘤素M及组蛋白H4水平,选取年龄、性别相似的健康者40例为健康对照组;依据脓毒症病人28 d预后分为生存组和死亡组,使用统计学软件分析临床资料,比较两组血清抑瘤素M及组蛋白H4的差异。结果脓毒症组、脓毒性休克组病人血清OSM[55.49(41.96,63.09)ng/L、108.03(58.22,86.44)ng/L比40.85(27.92,51.26)ng/L]及H4[29.93(25.09,31.74)μg/L、34.81(28.03,36.16)μg/L比25.85(22.50,28.23)μg/L]水平均高于健康对照组(P<0.05)。与脓毒症组相比,脓毒性休克组中血清OSM及H4水平更高(P<0.05);ROC曲线分析,H4、OSM及二者联合对脓毒症的诊断的AUC为0.79、0.76、0.83,两者联合效能高于两者单独检测;与存活组相比,死亡组病人血清OSM[108.98(53.59,103.32)ng/L比52.01(42.26,62.05)ng/L]和H4[36.94(29.96,40.58)μg/L比27.45(25.37,28.59)μg/L]水平更高(P<0.05)。OSM、H4及联合分别绘制ROC曲线计算AUC分别为0.76(0.61.0.92)、0.82(0.69,0.95)和0.89(0.79,0.99)。结论抑瘤素M和组蛋白H4能用于对脓毒症早期诊断和预后评估,两者联合对脓毒症病人诊断效能及近期预后评估的能力有所提升。

急性冠状动脉综合征患者血清Reg3β、OSM水平的变化及临床意义

目的探讨急性冠状动脉综合征(ACS)患者血清再生胰岛衍生蛋白3β(Reg3β)、抑瘤素M(OSM)水平的变化及临床意义。方法选取2021年9月—2022年12月海南医学院附属海南医院/海南省人民医院急诊科收治ACS患者183例为ACS组,同期医院健康体检者65例为健康对照组,再根据随访12个月预后将ACS患者分为不良预后亚组(52例)和良好预后亚组(131例)。采用酶联免疫吸附法检测血清Reg3β、OSM水平;Spearman相关性分析ACS患者血清Reg3β与OSM水平的相关性;多因素Logistic回归和ROC曲线分析ACS患者不良预后的危险因素及血清Reg3β、OSM水平对其预测价值。结果与健康对照组比较,ACS组血清Reg3β、OSM水平升高(t/P=7.748/<0.001、9.450/<0.001);183例ACS患者12个月不良预后发生率为28.42%(52/183);与良好预后亚组比较,不良预后亚组血清Reg3β、OSM水平升高(t/P=7.390/<0.001、7.087/<0.001);ACS患者血清Reg3β与OSM水平呈正相关(r s/P=0.793/<0.001);年龄增加、KILLIP分级≥Ⅱ级、Gensini评分增加和Reg3β升高、OSM升高是ACS患者不良预后的独立危险因素[OR(95%CI)=1.071(1.008~1.138)、3.709(1.186~11.600)、1.045(1.022~1.067)、1.014(1.007~1.021)、1.007(1.004~1.010)];血清Reg3β、OSM水平及二者联合预测ACS患者不良预后的曲线下面积(AUC)分别为0.784、0.789、0.861,二者联合的AUC大于血清Reg3β、OSM水平单独预测(Z/P=2.955/0.003、2.696/0.007)。结论ACS患者血清Reg3β、OSM水平升高,并与不良预后密切相关,且二者联合预测ACS患者不良预后的价值较高。

新型生物标志物MDW HMGB1及OSM在脓毒症中的应用价值

虽然脓毒症在诊断和治疗方面有所改进,但重症监护病房(ICU)住院患者的发病率和病死率仍然很高。临床尚不能完全做到及早发现脓毒症,但对于已确诊的脓毒症患者,就应及早干预脓毒症进展,降低其病死率。因此,目前需要及早识别、较好预测脓毒症结局的生物标志物,以帮助临床医生解决其实际问题。近年来脓毒症相关生物标志物的研究广受外界关注,现重点对脓毒症早期诊断、风险预测相关标志物单核细胞分布宽度(MDW)、高迁移率族蛋白B1(HMGB1)及抑癌蛋白M(OSM)的最新研究进展做一综述。

Egr-1基因调控序列连接OSM cDNA表达质粒的构建及其在黑色素瘤细胞中的表达

ＯＳＭ是一种对黑色素瘤细胞显示抑制作用的细胞因子．为进行ＯＳＭ针对黑色素瘤的基因－放射治疗研究，构建了小鼠Ｅｇｒ－１基因调控序列引导入ＯＳＭｃＤＮＡ真核表达质粒（ｐＥＯ），ｐＥＯ质粒转染小鼠Ｂ－１６黑色素瘤细胞，经Ｇ４１８和抗人ＯＳＭ抗体的筛选，获得了稳定表达ＯＳＭ的克隆细胞（ｐＥＯ－１细胞），ＯＳＭ表达量可达５．９７ｎｇ每１０５细胞天，分子量为３２ｋＤ．ｐＥＯ－１细胞用一定浓度Ｈ２Ｏ２处理后ＯＳＭ表达量可提高６２％。

SOCS-3对OSM诱导的肾小管上皮细胞转分化的影响

目的观察细胞因子信号传导抑制蛋白-3(suppressors of cytokine signaling,SOCS-3)对抑瘤素M(oncostatin M,OSM)诱导的人肾小管上皮细胞转分化的影响。方法体外培养人肾近曲小管上皮细胞株(HKC),用Lipofectamine 2000分别转染pCR3.1/SOCS-3表达质粒和pCR3.1空质粒载体,G418筛选阳性克隆,应用OSM(10 ng/ml)进行刺激。培养48 h后收集细胞及上清液,采用Western blot检测SOCS-3、CK18、α-SMA和磷酸化信号传导及转录激活因子3(phospho-Signal transducers and activators of transcription 3,p-STAT3)的表达;采用酶联免疫吸附实验测定细胞上清液中Ⅰ型胶原(collagenⅠ,ColⅠ)和纤维连接蛋白(fibronectin,FN)的分泌;采用RT-PCR检测SOCS-3 mRNA的表达。结果与对照组相比,OSM刺激组肾小管上皮细胞α-SMA和p-STAT3蛋白表达增加,细胞培养上清液ColⅠ和FN的分泌增加,而CK18蛋白表达减少。SOCS-3过表达能抑制OSM刺激引起的α-SMA和p-STAT3蛋白表达,减少ColⅠ和FN的分泌,同时能够部分恢复OSM刺激引起的CK18蛋白表达。结论 SOCS-3过表达能抑制OSM诱导的肾小管上皮细胞转分化,此过程可能与p-STAT3的磷酸化受抑有关。

STAT蛋白在抑瘤素M诱导的肾小管上皮细胞损伤中的作用

目的探讨STAT蛋白在抑瘤素M(oncostatin M,OSM)诱导的肾小管上皮细胞表型转化及分泌功能中的作用。方法体外培养人肾近曲小管上皮细胞,分为对照组(C组)、OSM(20 ng/ml)组(OSM组)、OSM+雷帕霉素(100 ng/ml)组(OSM+R组)和OSM+氟达拉滨(100 ng/ml)组(OSM+F组)。培养72 h后收集细胞及上清液,透射电镜观察细胞超微结构改变;免疫细胞化学和Western blot法检测CK18、α-SMA蛋白表达;采用Western blot法检测信号转导及转录激活因子(STAT1、STAT3、pSTAT1、p-STAT3)的表达;酶联免疫吸附实验测定细胞上清液中Ⅰ型胶原(collagenⅠ,ColⅠ)和纤维连接蛋白(fibronectin,FN)的分泌。结果与对照组相比,细胞经OSM刺激后CK18的表达下调,而α-SMA的表达上调并分泌过多的细胞外基质蛋白ColⅠ和FN;此外,OSM还可磷酸化激活STAT1和STAT3。OSM的上述作用可被雷帕霉素和氟达拉滨所阻断。结论 OSM具有促纤维化特性,而STAT1和STAT3信号活化在OSM介导的纤维化进程中发挥同等重要的作用。

Identification of cytokines involved in hepatic differentiation of mBM-MSCs under liver-injury conditions

AIM: To identify the key cytokines involved in hepatic differentiation of mouse bone marrow mesenchymal stem cells (mBM-MSCs) under liver-injury conditions. METHODS: Abdominal injection of CCl4 was adopted to duplicate a mouse acute liver injury model. Global gene expression analysis was performed to evaluate the potential genes involved in hepatic commitment under liver-injury conditions. The cytokines involved in hepatic differentiation of mBM-MSCs was function-ally examined by depletion experiment using specifi c antibodies, followed by rescue experiment and direct inducing assay. The hepatic differentiation was characterized by the expression of hepatic lineage genes and proteins, as well as functional features. RESULTS: Cytokines potentially participating in hepatic fate commitment under liver-injury conditions were initially measured by microarray. Among the up-regulated genes determined, 18 cytokines known to closely relate to liver growth, repair and development, were selected for further identif ication. The f ibroblast growth factor-4 (FGF-4), hepatocyte growth factor (HGF) and oncostatin M (OSM) were fi nally found to be involved in hepatic differentiation of mBM-MSCs under liver-injury conditions. Hepatic differentiation could be dramatically decreased after removing FGF-4, HGF and OSM from the liver-injury conditioned medium, and could be rescued by supplementing these cytokines. The FGF-4, HGF and OSM play different roles in the hepatic differentiation of mBM-MSCs, in which FGF-4 and HGF are essential for the initiation of hepatic differentiation, while OSM is critical for the maturation of hepatocytes. CONCLUSION: FGF-4, HGF and OSM are the key cytokines involved in the liver-injury conditioned medium for the hepatic differentiation of mBM-MSCs.

抑瘤素-M(OSM)在GST融合表达系统中的表达、纯化和活性测定

抑瘤素Ｍ是一种具有多种生物活性的细胞因子，具有重要的研究价值和潜在的应用前景。基于ＧＳＴ融合表达载体，构建了一个ＯＳＭ的高效表达系统，诱导表达后融合蛋白占全菌蛋白的５０％以上，在低温诱导的条件下，可溶性蛋白中融合蛋白的含量可达１５％。在对包涵体形式的融合蛋白变复性的基础上，通过亲和层析一步纯化达到９０％左右的纯度。对融合蛋白进行了活性测定，结果提示了Ｎ端的头两个氨基酸对ＯＳＭ的生物活性是重要的。

人抑瘤素M在毕赤酵母中的高效分泌表达

目的:在毕赤酵母中高效分泌表达重组人抑瘤素M(rhOSM)。方法:以人胚胎组织DNA为模板通过PCR技术获得hOSM基因,构建毕赤酵母真核表达载体pPICZαC-hOSM,电转化毕赤酵母菌株X-33,PCR法筛选阳性克隆,SDS-PAGE和Western blotting方法筛选能够稳定、高效分泌表达rhOSM的酵母工程菌。结果:经PCR法获得了hOSM基因,培养液上清经SDS-PAGE和Western blotting证实获得了相对分子质量约为28000的rhOSM,表达量为45mg·L-1。结论:毕赤酵母表达系统能够稳定、高效分泌表达rhOSM,摇瓶规模表达量为45mg·L-1。

质粒DNA同源重组法构建腺病毒载体hosm

目的构建含hosm基因的重组腺病毒载体,观察其对肿瘤细胞生长的影响。方法用脂质体介导的粒DNA同源重组方法构建含人osm基因的重组缺陷型腺病毒载体,用PCR法鉴定所构建的ad-hosm栽体。结果 成功构建了含hosm基因的重组腺病毒栽体。结论 脂质体介导的质粒DNA同源重组法能有效构建重组腺病毒载体;PCR法简化了阳性重组腺病毒的鉴定程序,为进一步研究重组腺病毒介导人osm基因对肿瘤细胞的生物学活性的影响提供了条件。

PCR检定OSMcDNA转染细胞中基因组整合与转录

用ＰＣＲ和ＲＴＰＣＲ方法对人ＯＳＭｃＤＮＡ转染的小鼠黑色素瘤细胞进行基因组整合和ｍＲＮＡ 转录的检定．基因组整合检定时， 采用与调控序列和ｃＤＮＡ 序列相对应的上、下游引物， 以连续的转录单位进行扩增， 能够更准确地反映整合与表达的关系； ｍ ＲＮＡ 检定时， 采用与ｃＤＮＡ序列和质粒克隆位点与加ｐｏｌｙＡ 信号之间序列相对应的上、下游引物，

抑瘤素M联合达卡巴嗪抑制黑色素瘤细胞B16的增殖

目的:通过体内外实验探讨抑瘤素M(OSM)联合达卡巴嗪(DTIC)对小鼠黑色素瘤细胞B16的抑制作用。方法:在体外分别采用MTT法和FCM法检测达卡巴嗪单药以及联合OSM对黑色素瘤B16细胞增殖和凋亡的影响;Hochest染色法检测达卡巴嗪单药以及联合OSM对黑色素瘤B16细胞的细胞核形态学变化,研究OSM联合DTIC对黑色素瘤B16细胞的抑制作用;体内实验将黑色素瘤细胞B16接种于小鼠,观察OSM、DTIC及DTIC联合OSM治疗对小鼠的成瘤性的影响。结果:体外实验中OSM、DTIC或DTIC联合OSM对黑色素瘤B16细胞的增殖抑制率分别为11.2±2.3%,25.3±4.6%和32.5±3.8%,差异具有统计学意义(P<0.05),诱导黑色素瘤B16细胞的凋亡率分别为1.32±0.42%,10.64±2.13%和15.86±2.76%,差异具有统计学意义(P<0.05)。在形态学上,DTIC联合OSM可明显引起细胞核破碎增加;在体内实验中,DTIC相对于对照组能明显抑制小鼠黑色素瘤的生长,DTIC联合OSM能增加DTIC的抑瘤作用。结论:OSM联合DTIC体外可以明显抑制黑色素瘤B16细胞增殖,诱导其凋亡,为黑色素瘤的治疗提供了一种新的可能性方案。

血清抑瘤素M、腱糖蛋白-C水平与2型糖尿病合并急性冠脉综合征的关系研究

目的探讨血清抑瘤素M(OSM)、腱糖蛋白-C(TN-C)水平与2型糖尿病(T2DM)合并急性冠脉综合征(ACS)的关系。方法选取该院2018年6月至2020年6月收治的80例T2DM合并ACS患者作为合并组,纳入同期收治的单纯T2DM、ACS患者各60例作为T2DM组、ACS组。比较3组血清OSM、TN-C水平及空腹血糖(FPG)、糖化血红蛋白(HbA1c)、甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、肌钙蛋白I(cTnI)水平,分析T2DM合并ACS患者血清OSM、TN-C水平与其他检测指标的相关性,经Logistic多元回归模型分析T2DM患者发生ACS的危险因素。结果合并组血清OSM、TN-C水平及TC、LDL-C、CK、CK-MB、cTnI高于T2DM组、ACS组,合并组FPG、HbA1c、FINS、HOMA-IR、Gensini积分高于ACS组,差异有统计学意义(P<0.05)。合并组血清OSM、TN-C水平与TC、LDL-C、CK、CK-MB、cTnI、Gensini积分呈正相关(P<0.05)。Logistic多因素回归分析显示,高血压病史、TC≥3.55 mmol/L、LDL-C≥2.21 mmol/L、CK≥179.88 U/L、CK-MB≥47.12 U/L、cTnI≥1.25μg/L、OSM≥26.52 pg/mL、TN-C≥10.92 ng/mL是T2DM患者发生ACS的危险因素(P<0.05)。结论T2DM合并ACS患者的血清OSM、TN-C水平明显升高,二者是T2DM发生ACS的独立危险因素,OSM、TN-C可作为评估T2DM合并ACS病情进展的辅助指标。

抑瘤素M及其受体在IBD患者中的表达以及与抗TNF治疗中耐受反应发生的关系分析

目的研究抑瘤素M(OSM)及其受体(OSMR)在IBD患者中的表达以及与抗TNF治疗中耐受反应发生的关系。方法选取我院接受的61例溃疡性结肠炎患者,采用实时荧光定量PCR方法,分别检测患者炎症程度不同的结肠部位的OSM和OSM受体的表达情况;所有患者均接受英夫利昔单抗进行抗TNF治疗,观察在治疗过程中OSM和OSMR表达情况与抗TNF治疗耐受反应出现的相关性。结果与健康对照组相比,OSM和OSMR在患者非炎症部位结肠组织表达无显著性差异(P>0.05),炎症部位和溃疡部位结肠组织表达差异有统计学意义(P<0.01)。此外,OSM和OSMR的表达与抗TNF治疗过程中耐受反应的出现呈正相关。结论 OSM和OSMR在IBD患者的结肠组织中高表达,且其表达量与抗TNF治疗耐受反应的出现密切相关。OSM和OSMR对IBD患者抗TNF治疗中耐受反应发生的诊断具有一定的潜在应用价值。